Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been in clinical use for the treatment of diabetes and also been reported to be neuroprotective in ischemic stroke. The quinoxaline 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) is an agonist and allosteric modulator of the GLP-1R with the potential to increase the affinity of GLP-1 for its receptor. The aim of this study was to evaluate the neuroprotective effects of DMB on transient focal cerebral ischemia. In cultured cortical neurons, DMB activated the GLP-1R, leading to increased intracellular cAMP levels with an EC 50 value about 100 fold that of exendin-4. Pretreatment of neurons with DMB protected against necrotic and apoptotic cell death was induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by GLP-1R antagonism. In C57BL/6 mice, DMB was orally administered 30 min prior to middle cerebral artery occlusion (MCAO) surgery. DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effects were mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. DMB exhibited anti-apoptotic effects by modulating Bcl-2 family members. These results provide evidence that DMB, a small molecular GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO. Taken together, these data suggest that DMB is a potential neuroprotective agent against cerebral ischemia.
Introduction
Ischemic stroke is a leading cause of adult morbidity and mortality worldwide with very limited treatment options [1] . Tissue plasminogen activator (tPA), which acts by dissolving clots after intravenous injection, is the only Food and Drug Administration (FDA)-approved therapy for the treatment of stroke. However, only about 2% of stroke patients are eligible for tPA treatment. This lack of treatment options highlights the need for new therapeutics aimed at the prevention and treatment of ischemic stroke.
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide secreted from the L-cells of the small intestine [2] . GLP-1 exerts its effects by binding to GLP-1 receptor (GLP-1R), a member of the class B family of seven transmembrane G protein-coupled receptors (GPCRs) [3] . GLP-1R is widely expressed in the brain, and GLP-1R activation mediates neuroprotection in animal models of Alzheimer's, Parkinson's, Huntington's, stroke and other degenerative diseases [4] [5] [6] [7] . GLP-1 and analogues cross the blood-brain barrier, protect memory formation or motor activity, enhance neurogenesis, reduce apoptosis, protect neurons from oxidative stress, and reduce chronic inflammation response [6, 7] . Therefore, GLP-1R is considered to be an effective and promising therapeutic target for nervous system diseases.
The GLP-1R stimulates cAMP by coupling to the Gαs subunit. Serine protease dipeptidyl peptidase-IV rapidly degrades GLP-1 in plasma, resulting in a half-life of only about 1 min [8] . , Lily), semaglutide once-weekly (NovoNordisk) and others are in various stages of clinical trials [9] . These GLP-1 mimetics possess favorable pharmacokinetic properties, including reduced frequency of injections and improved glycemic control throughout the day [9, 10] . Recent studies have reported that these GLP-1 analogs, such as exendin-4 and liraglutide, exert neuroprotective effect on ischemic stroke [4, 5, [11] [12] [13] [14] [15] . Because hyperglycemia is one of the leading risk factors for ischemic cerebrovascular diseases [16] , it provided a potential clinical use of GLP-1R agonists for the treatment of stroke in T2D patients or individuals at high risk to suffer from a stroke (e.g. pretreatment strategies). Unfortunately, GLP-1 and its analogues require administration by subcutaneous or intravenous injection. Hence, the development of an orally active non-peptide small molecular weight GLP-1R agonist is desirable.
Recently, a series of substituted quinoxalines and a cyclobutane derivative were reported to serve as a scaffold for nonpeptide GLP-1R agonists. One such candidate, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB , Fig 1) , is a quinoxaline compound that acts as an agonist and allosteric modulator of the GLP-1R. DMB has the potential to increase the affinity of GLP-1 for its receptor and stimulate cAMP, which potentiates glucosedependent insulin release in β-cells. However, the efficacy of DMB on the GLP-1R in the brain has not been previously reported. In the current study, we evaluated the neuroprotective effects of DMB as a small molecular GLP-1R agonist on transient focal ischemia induced cerebral damage with an oxygen-glucose deprivation (OGD) model in cultured neurons and MCAO and reperfusion model in mice.
Antibodies against β-actin, exendin-4 and exendin (9-39) were purchased from Sigma-Aldrich (Saint Louis, MO, USA) along with the Hoechst 33258, and PI. The plasma insulin ELISA kit was purchased from the Millipore Corporation (Billerica, MA, USA); cAMP parameter assay kit and TUNEL staining in situ cell death detection kit were purchased from Roche (Minneapolis, MN, USA) and the LDH detection kit was purchased from Jiancheng Inc. (Nanjing, Jiangsu, China). CeneChem Co., Ltd. (Shanghai, China) prepared the pGV118 lentiviral vector encoated shRNA targeting the GLP-1R.
Primary mouse cortical neuronal culture
Primary cortical neurons were taken from 18-day-old neonatal C57BL/6 mice. Neurons were dissociated, minced, and trypsinized with 0.125% trypsin and then seeded into plates of 6 or 96 wells using DMEM containing 20% fetal bovine serum and at a density of approximately 2,500 cells/mm 2 . The culture medium was then replaced by neuron-basal medium supplemented with 2% B27 at 37°C. Neurons were cultured for 7 days and then used for further experiments.
Determination of cAMP
Primary culture neurons were seeded into 96 well culture plates for 7 days. LV-shGLP-1R (10 5 TU/ml) was added 4 days and exendin (9-39) (1 μM) was added 30 min prior to the addition of DMB (10
-10 −4 μM) or exendin-4 (10 −10 -10 −6.5 μM) to the culture wells. Cells were allowed to incubate for 0-30 min following treatment with DMB or exendin-4. A cAMP assay kit was then used to determine cAMP levels according to the manufacturer's instructions. All data were subsequently normalized to the response of 1 mM GLP-1.
Oxygen-glucose deprivation (OGD)
OGD on primary neuronal cultures was performed as previously reported [17] . Briefly, cultured primary cortical neurons were washed with PBS 3 times, then placed in glucose-free EBSS buffer and stored in an anoxic chamber filled with 95% N 2 and 5% CO 2 for 6 h. The culture medium was then replaced by fresh neuron-basal medium supplemented with 2% B27 and the neurons were returned to normoxic conditions for reoxygenation for 12 h. 
Cell viability assay
The cell survival and death rates of the neurons were determined using an MTT and LDH assay 24 h after OGD injury. For the MTT assay, MTT was added at a final concentration of 0.5 mg/ml and incubated at 37°C for 4 h. The culture medium was then replaced with DMSO and the optical density was determined at 490 nm. LDH activity was measured with an LDH assay kit according to the manufacturer's instructions. The optical density was measured at a wavelength of 490nm. Neurons maintained under normoxic conditions were defined as 100% viable. The viability of neurons exposed to OGD conditions is expressed as a percentage compared to cells under normoxic conditions.
Hoechst/PI double staining
Hoechst/PI staining was performed 24 h after OGD. Briefly, Hoechst 33258 and PI were added into the culture medium at a final concentration of 10 μg/ml for 15 min and then fixed with formaldehyde for 30 min. Neurons were observed under a fluorescent microscope (Olympus BX61, Japan). Hoechst was excited at 340 nm and PI was excited at 620 nm.
Experimental animals and drug treatment
Adult male C57BL/6 mice weighing 18-22 g were used in our research. The Animal Care and Use Committee of the Fourth Military Medical University approved all animal protocols. Mice were maintained in a climate-control room with a 12 h light-dark cycle with access to food and water ad libitum throughout the experimental period. All surgery was performed under anesthesia, every effort was made to minimize the number of animals used and their suffering. After acclimation to the environment for 7 days, mice were treated with DMB (5 μmol/kg, orally) and/or exendin-4 (10 nmol/kg, i.p.) 30 min prior to MCAO.
Determination of blood glucose and plasma insulin levels DMB (5 μmol/kg) was orally administrated to C57BL/6 mice and blood samples collected at 0, 30, 60 and 120 min after administration. The plasma insulin level was determined with an ELISA kit. The blood glucose level was determined using a glucometer (Roche Diagnostics, Mannheim, Germany).
Animal model of focal cerebral ischemia
The middle cerebral artery occlusion procedure was conducted as previously described [18] . Briefly, the animals were anesthetized with 1% pentobarbital sodium. The right carotid region was exposed and a 6-0 nylon filament inserted through the external carotid artery and gently advanced 11 mm to occlude the middle cerebral artery (MCA) for 60 min. Reperfusion was performed by withdrawing the nylon monofilament.
Neurological deficits score assay and infarct volume measurement
The neurological deficit scores were evaluated in a blinded fashion 24 h after MCAO and reperfusion based on Bederson's score standard [19] . Specifically, grade 0 represents no observed deficit; grade 1 represents flexion to contralateral torso and forelimb; grade 2 represents a decreased resistance to lateral push but without circling; grade 3 represents leaning to affected side; and grade 4 represents no spontaneous locomotor activity. Dead animals were excluded in the scoring scale. After evaluation of neurological deficits, the infarct volume was measured by TTC staining, which has been widely used for accurately reflecting the extent of irreversible ischemic damage in cerebral tissues [20] . Briefly, the brain was removed and frozen at -20°C for 30 min and then sectioned into slices 1 mm thick. The slices were then incubated in a 1.5% TTC solution at 37°C for 30 min and fixed in paraformaldehyde. Samples were digitally photographed and the percentage of the infarct volume with respect to the total brain volume was quantified with Photoshop CS4.
Silencing of the GLP-1R by LV-shGLP-1R
A specific sequence of shRNA targeting to GLP-1R mRNA (GenBank Accession No. NM_021332.2, 608-628) was constructed into a pGV118 lentiviral vector. For culture neurons, LV-shGLP-1R was dissolved in an enhanced infection solution and added to medium 4 days prior to drug treatment at the titre of 10 5 TU/ml for 12 h. For C57 mice, LV-shGLP-1R was stereotaxically delivered into the ipsilateral ventricle (bregma: -0.4 mm, dorsoventral: 0.7 mm, lateral: 1.8 mm) 7 days before MCAO injury as previously described [21] . Silencing efficiency was assayed by detecting GLP-1R levels in neurons or the ipsilateral ischemic penumbra area of C57 mice (S1 Fig).
TUNEL staining
TUNEL staining was performed 24 h after MCAO as previously described [22] . Mice were deeply anesthetized and perfused with cold saline followed by 4% paraformaldehyde. The ipsilateral ischemic penumbra section (20 μm) was selected for TUNEL staining. TUNEL staining was performed using an in situ cell death detection kit performed according to the manufacturer's protocol. The stained sections were photographed with a confocal fluorescent microscope. The apoptotic neurons were counted and results are expressed as TUNEL positive cells per mm 2 .
Western Blot
Protein samples in cultured neurons were collected 7 days after plating. The protein samples were extracted from the ipsilateral ischemic penumbra area 24 h after MCAO or 7 days after stereotaxically injecting LV-shGLP-1R in the mice. After homogenization in cold lysis buffer containing 1 nM PMSF, protein levels were determined using bichioninic acid. A 20 μg protein sample was loaded onto an SDS page gel and transferred to polyvinylidene fluoride membranes and blocked in TBS containing 5% nonfat milk for 2 h at room temperature. The membranes were incubated with anti-GLP-1R (1:1,000), anti-PKA (1:1,000), anti-p-CREB (1:500), anti-CREB (1:500), anti-Bax (1:500), anti-BCL-2 (1:500; Santa), or anti-β-actin (1:5,000) overnight at 4°C, then incubated with goat anti-mouse or anti-rabbit IgG secondary antibodies (1:10,000) for 1 h. The blots were visualized and quantified with densitometry.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0. All data except for neurological scores are expressed as mean±SD and differences between groups were analyzed by one-way ANOVA followed by a Dunnett T-test. The neurological scores were analyzed with the Kruskal-Wallis test followed by the Mann-Whitney U-test with the Bonferroni correction. Significant differences were accepted if the p value was < 0.05.
Results

The GLP-1R was present in cortical neurons and activated by DMB
A Western blot was used to detect the presence of the GLP-1R in both cortical neurons and β-cells, which were used as a positive control (Fig 2A and 2B) . In cortical neurons incubated with DMB (1 μM), we observed a rapid, transient elevation of intracellular cAMP levels. The cAMP reached its peak level after 15 min and then returned toward baseline at 30 min (Fig 2C) . These data demonstrate that the GLP-1R receptor is present in primary cortical neurons and can be activated by DMB.
The mechanism of GLP-1R receptor activation by DMB is different than exendin-4
We compared the effect of DMB on the GLP-1R in neurons with exendin-4, a long lasting peptide agonist that has been used clinically. The results show that DMB mediated cAMP generation after a 15 min incubation period with a 90% efficacy relative to stimulation by 1 mM GLP-1; DMB displayed an EC 50 value about 100 fold compared with exendin-4 ( Fig 3A) . To further evaluate the mechanism, we exposed the cells to exendin (9-39) (1 μM), an orthosteric competitive antagonist [23, 24] . The results show that exendin (9-39) resulted in nearly complete inhibition of the cAMP generation stimulated by exendin-4, but had no effect on the cAMP generated by DMB (Fig 3A) . However, LV-shGLP-1R (10 5 TU/ml) diminished the stimulation of cAMP generated by both exendin-4 and DMB (Fig 3A) . These results indicate that the An Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Stroke interaction of DMB with the GLP-1R in neurons is through a different mechanism than exendin-4. DMB reportedly exhibits agonist and positive allosteric modulator activity at the GLP-1R without competing with exendin-4 for receptor binding [25] . Thus, the effect of DMB on neurons in the presence of exendin-4 was evaluated. Results indicate that co-incubation of DMB (10 μM) with exendin-4 (100 nM) further stimulates cAMP generation; however, the combination of GLP-1 (100 nM) and exendin-4 (100 nM) did not exert a similar effect ( Fig  3B) . These results indicate that DMB and exendin-4 induce GLP-1R activation in an additive manner in neurons.
DMB decreased OGD induced death of primary cultured neurons
OGD and reperfusion is an in vitro model that mimics the condition of ischemia-reperfusion injury [26] . Therefore, the action of DMB against cerebral ischemia in vitro was studied in this model. Cell viability assays by MTT and LDH showed that OGD and reperfusion injury lead to a decrease in neuronal survival compared with cells under normoxic conditions. Pretreatment with DMB (1 μM) and exendin-4 (10 nM) significantly increased the cell survival rate compared with the OGD only group. The GLP-1R peptide antagonist exendin (9-39) (1 μM) had no impact on the neuroprotective efficiency of DMB. However, silencing the GLP-1R by LVshGLP-1R (10 5 TU/ml) almost totally attenuated this effect (Fig 4A and 4B) . As expected, the results of Hoechst 33258/PI double staining showed that the necrotic and apoptotic neurons caused by OGD and reperfusion were reversed by DMB and exendin-4. LV-shGLP-1R (10 5 TU/ ml) but not exendin (9-39) (1 μM) blocked the beneficial effects of DMB (Fig 4C and 4D) . 
DMB had no impact on plasma insulin and glucose levels in nondiabetic mice
We assessed the effect of DMB on plasma insulin and glucose levels because insulin and glucose levels can influence brain injury. GLP-1R agonists have the potential to stimulate insulin secretion in a glucose-dependent manner. It is rational to speculate that DMB had no impact on plasma insulin and glucose level and we can take it as the expected result, but actually there is no data on the effect of DMB in normal animals. Therefore, the effect of DMB on plasma insulin and glucose levels was determined in normal mice. Results showed no significant differences in plasma insulin ( Fig 5A) and blood glucose (Fig 5B) levels after administration of DMB (5 μmol/ kg, orally). These two parameters were stable in the mice during the 120 min treatment period.
DMB improved functional outcomes and reduced infarct size in stroke model
We further evaluated the neuroprotective effects of DMB on cerebral ischemia in MCAO mice by comparing neurological deficits and infarct volume. MCAO injury caused an obvious increase in the neurological deficit score. Oral administration of DMB (5 μmol/kg), intraperitoneal injection of exendin-4 (10 nmol/kg) as well as the combination of these two drugs significantly decreased the neurological deficit caused by MCAO. The effect of DMB was reversed by intracerebroventricular infusion of LV-shGLP-1R (Fig 6A) . The infarct volume assessed using TTC staining was in accordance with the neurological deficit scores. Oral administration of DMB (5 μmol/kg) and intraperitoneal injection of exendin-4 (10 nmol/kg) reduced the infarct volume caused by MCAO. The combination of DMB (5 μmol/kg, oral) and exendin-4 (10 nmol/kg, i.p.) further improved the beneficial efficacy. Silencing of GLP-1R by LV-shGLP-1R, however, diminished the neuroprotective effects of DMB (Fig 6B and 6C ).
6. DMB stimulated the cAMP-PKA-CREB signaling pathway after MCAO cAMP signaling leads to phosphorylation and activation of CREB through PKA, stimulating gene expression that promotes neuronal viability [27] [28] [29] . Thus, the effect of DMB on this signaling pathway after MCAO was evaluated. Results show that PKA and p-CREB (Fig 7A-7C ) levels were significantly decreased after MCAO injury in the ischemic penumbra area. These trends were reversed by pretreatment with DMB (5 μmol/kg). This effect, however, was diminished by intracerebroventricular infusion of LV-shGLP-1R. The presence or absence of MCAO and DMB had no impact on the expression of total CREB levels (Fig 7A and 7D) . These results indicate that DMB stimulates the cAMP-PKA-CREB signaling pathway via activation of the GLP-1R.
DMB mediated anti-apoptotic effect against MCAO injury
Apoptosis is suggested to be one of the leading contributors to neuronal injury after cerebral ischemia [30, 31] . Neuron apoptosis in ipsilateral ischemic penumbra was evaluated by TUNEL staining, a specific staining of DNA fragmentation which results from apoptotic signaling cascades. Only a few TUNEL-positive cells were observed in the sham group; however, MCAO caused a significant increase in TUNEL-positive cells 24 h after injury. In contrast, DMB (5 μmol/kg, orally) significantly decreased the number of TUNEL-positive cells compared with the MCAO group (Fig 8A and 8B) .
Bcl-2 and Bax play an important role in the regulation of neuronal apoptosis. Bcl-2 is an anti-apoptotic protein while Bax can promote apoptosis. Western blot results showed a strong downregulation of Bcl-2 and upregulation of Bax 24 h after cerebral ischemia in the ipsilateral ischemic penumbra area. This trend, however, was reversed by oral administration of DMB (5 μmol/kg) (Fig 8C and 8D) . These results indicate that DMB has an anti-apoptotic effect against cerebral ischemia.
Discussion
GLP-1 can be released from L cells following the ingestion of food. GLP-1 exerts many biological effects by activating the GLP-1R signaling pathway, including the induction of glucosedependent insulin release, inhibition of glucagon secretion and stimulation of β-cell proliferation [32] . As previously stated, GLP-1 based drugs have proven to be beneficial for the treatment of T2D.
The GLP-1R belongs to the class B family of G-protein coupled receptors (GPCRs). Upon GLP-1R activation, the major signaling pathway involves activation of adenylyl cyclase via stimulatory Gα, leading to an increase in intracellular cAMP levels and a series of subsequent signaling events that regulate various cell functions [33] . The GLP-1R is distributed in many peripheral tissues (e.g. pancreatic islets, heart, kidney, and gastrointestinal tract) and is also An Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Stroke widely expressed in many regions of the brain [32, 33] . Recent research has showed neuroprotective properties against ischemic stroke by drugs targeting GLP-1R [4, 5, [11] [12] [13] [14] [15] . Therefore, the GLP-1R is emerging as a new therapeutic target for the treatment of cerebral ischemic stroke.
Diabetes is believed to be a generally accepted risk factor related with episodes of stroke [16] . GLP-1R agonists are in clinical use for the treatment of diabetes and several studies indicate that they may be useful in the treatment of ischemic stroke, but the neuroprotective efficiency of orally administered low molecular weight agonists has not been reported. It is difficult to identify nonpeptide, low molecular weight GLP-1R agonists that are orally active. GLP-1R activation by peptide agonists requires binding predominantly to the large N-terminal domain of the receptor [34] . It is difficult for the surrogate small molecule agonists to mimic this action due to the size of the peptide ligands and their mechanism for receptor activation. Small ligands may not be able to fully mimic the actions of larger peptide agonists. Nonetheless, several small molecules have been successfully identified as GLP-1R agonists, including DMB and Boc-5-a large cyclobutane derivative.
The GLP-1R is comprised of eight hydrophobic domains, seven of which span the membrane, with a further extracellular N-terminal domain. GLP-1 and its peptide agonists bind to the receptor in an orthosteric manner. Recently published data reported that a range of polyclonal anti-GLP-1R antibodies cannot be used to detect GLP-1R in immunohistochemistry or western blotting [35] [36] [37] and with no validation of antibody specificity in paraffin-embedded tissues. Although these findings revealed substantial problems with the sensitivity and specificity of antibody against GLP-1R used for the detection of the GLP-1R in various tissues, there are still a lot of researches performed by western blot analysis to detect the expression of GLP-1R [38] [39] [40] . We found that primary cortical neurons expressed GLP-1R at protein levels, and However, DMB reportedly interacts with the GLP-1R at an allosteric site that has been speculated to be a cavity located near the transmembrane 5 and 6 region [41] . Exendin blocked the effects of GLP-1 by competitively binding the extracellular domain of the GLP-1R [24, 42] . Thus, the cAMP generated by DMB was not inhibited by exendin . DMB has been shown to potentially increase the affinity of peptide agonists [25] . Here, we show similar results in which the neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by a GLP-1R antagonist. Moreover, DMB activated the GLP-1R-leading to increased intracellular cAMP levels in cultured cortical neurons with an EC 50 value approximately 100 fold compared with exendin-4.
Neuroprotective strategies aimed at decreasing brain damage after ischemic stroke have failed to be translated into the clinical setting along the past decades [43] . Up to now, tPA is still the only approved pharmacological treatment for ischemic stroke. Although most of the current therapies are focused on posttreatment after cerebral ischemia, accumulating lines of evidence have demonstrated the efficacy of pretreatment therapies which could induce neuroprotection against cerebral ischemic injury. GLP-1R agonist exendin-4 is in clinical use for the treatment of diabetes and several studies indicated that it may be useful in the treatment of stroke [4, 5, [11] [12] [13] [14] . Li et al. found that intracerebral administration of exendin-4 induced neuroprotection and locomotor activity after stroke in the rat, and showed this neuroprotective effect was mediated by GLP-1R in GLP-1R knockout mice [4] . However, the findings have low clinical relevance since exendin-4 was given at stroke onset and via a route of administration not suitable for clinical applications. Teramoto et al. showed that transvenous administratration of exendin-4 provides neuroprotection against ischemic injury in mice at 1 h after MCAO, but the effect was lost at 3 h [5] . Another study by Darsalia et al. show neuroprotective efficacy of 50 μg/kg exendin-4 at 1.5 h and 3 h after stroke in both young healthy and aged diabetic/ obese mice, and the 5 μg/kg dose was neuroprotective at 1.5 h only [11] . Furthermore, other experiments have demonstrated that administration of exendin-4 before MCAO resulted in neuroprotection [4, [12] [13] [14] . Darsalia et al. that 4 weeks intraperitoneal pretreatment with exendin-4 before MCAO followed by another 4 weeks of exendin-4 treatment decreases brain damage in T2D rats [14] . GLP-1R agonists have been used in clinical for the treatment of T2D, hyperglycemia is one of the leading risk factors for ischemic cerebrovascular diseases [16] . So, it provided a potential clinical use of GLP-1R agonists for the treatment of stroke in T2D patients or individuals at high risk to suffer from a stroke (e.g. pretreatment strategies). Therefore, the pretreatment strategy was used in our current study based on these previous experiments. Data showed that oral administration of DMB with the therapeutic dose reduced cerebral infarct volume and neurological deficits caused by MCAO.
Stimulation of cAMP can trigger phosphorylation of CREB at serine 133, which plays an important role in neuronal development, synaptic plasticity, and memory formation. Phosphorylation of CREB leads to the expression of genes related to neuroprotection against ischemic insults [27] [28] [29] . We found that DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effect of DMB was mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. Activation of the GLP-1R resulted in an improvement of glycemic control, which could lower blood glucose and stimulate insulin release. Glucose level can influence brain injury. Insulin was reported to confer a neuroprotective effect in cerebral ischemia in MCAO [44] . Exendin-4 was reported to confer neuroprotective effect in a MCAO model of diabetic rats [14] . Thus, the peripheral effect on hyperglycemia induced by DMB is necessary to be excluded in non-diabetic mice. Since the level of blood glucose and plasma insulin was stable before and after DMB administration, and knock-down of the GLP-1R in the brain blocked the neuroprotective effect, we can conclude that DMB conferred the neuroprotective effect by activating GLP-1R in the brain.
These results demonstrate that DMB, a small molecular weight GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis in vivo and in vitro. Therefore, DMB represents a potential neuroprotective agent due to its ability to act alone or in combination with other peptide GLP-1R receptor agonists.
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